As clinical trial trials resume from pandemic-related delays and the industry begins to adapt to a new normal, sponsors should remain prepared for new and continued challenges as increases in COVID-19 cases in the United States, and other spikes in cases around the world will affect clinical trials in the coming months.
Many pharmaceutical and biotech companies have reported delays or postponements to clinical trials due to difficulties recruiting and treating participants, which, in turn, is a result of restricted travel and social distancing measures. In fact, a recent analysis by Medidata revealed that the number of new participants entering clinical trials remains 30 percent below where they were before the pandemic. Yet, it’s significantly higher than the approximately 70 percent decline in new participant starts in April.
In addition, most on-site monitoring of clinical trials has been delayed or postponed. Specific challenges facing clinical monitoring processes include tracking processes for visit schedules, protecting patient safety through compliant safety reporting, changing data collection modalities, and administering clinical outcomes assessments (COAs).
Also, many sites still use paper-based methods and have outdated or ageing technology infrastructures. However, incorporating newer innovations at sites and within trials requires protocol changes and site staff training for proper implementation, which can escalate costs. These challenges have been exacerbated by COVID-19, which has led to about a 30 percent increase in site costs due to sites being forced to adopt remote monitoring in response to inabilities to carry out responsibilities on-site.
As procedures typically carried out on-site continue to be managed remotely, sponsors will need to implement a remote clinical trial management strategy to mitigate further roadblocks that may arise and keep clinical trials moving forward.
Virtual from study start to data closeout through SMAs and electronic compliance tools
Incorporating remote monitoring, where on-site visits by a clinical research associate (CRA) are no longer viable, starts with reviewing study progress. Operational teams should review study-specific protocols and consider adopting remote services needed to reduce disruption to trial timelines, while staying compliant with local legislation.
Using a centralised site management associate (SMA) model, for example, can accelerate the adoption of remote and central monitoring. Located in regional hubs around the world, SMAs operate remotely (via phone or online) and serve as a single point of contact from the day a site is recruited until the day the study closes, thereby ensuring that site partners can always reach a knowledgeable study team member fluent in their own language and cultural context.
Through this centralised model, SMAs can remotely qualify and activate community study sites much more quickly than with traditional on-site support models. More importantly, SMAs can work with community sites to ease data submission. Where sites have electronic health records and data capture systems in place, much of the process can be automated, easing site administrative burdens. And finally, because disruptions to monitoring can have serious consequences for data validity, using an SMA model allows for remote source data verification (SDV), enabling sponsors to verify data without sending a CRA to a clinical trial site.
In addition to SMAs, sponsors can adopt automated regulatory intelligence and safety reporting solutions, ensuring compliance in an evolving regulatory environment and enabling visibility into the safety profile of a product throughout its lifecycle. Moreover, implementing remote management solutions can maximise health technology assessment (HTA) and health economics and outcomes research (HEOR) readiness and evidence generation planning. In addition, COA selection, design and validation can all be conducted remotely with the right strategies.
Remote management in a post-COVID world
The coronavirus pandemic forced the acceleration of digital health technologies, remote monitoring and virtual trial strategies within the clinical trials industry. As this pandemic subsides, the benefits to remote management will continue to grow its adoption into post-covid clinical trial designs and protocols as mitigation strategies, eventually becoming the industry standard. As our world continues to shift to an increasingly virtual reality, adopting remote monitoring solutions into clinical trial designs — whether initiating a new study or restarting a postponed study — will be necessary to keep drug development programmes on track today and tomorrow.
For more information on how ICON’s processes, technologies and experiences can help sponsors shift to a remote monitoring model to avoid COVID-19 related disruptions, contact us.
To learn more about how digital health technologies are accelerating clinical trial transformation, read our latest whitepaper Advancing digital endpoints: an end-to-end approach to managing wearable devices through clinical development
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel